MEDIA | 425 Business: EvergreenHealth Moves Forward with Trial for COVID-19 Treatment

Following a recent announcement from the National Institute of Allergy and Infectious Diseases (NIAID) regarding the use of the anti-viral Remdesivir to potentially treat COVID-19, Kirkland-based EvergreenHealth issued a statement that it would move forward with the next phase of its clinical research.

Over the preceding weeks, EvergreenHealth had become the first West Coast site — and the second globally — to participate in the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by NIAID. The trial is the first of its kind in the United States to evaluate an experimental treatment for COVID-19.

Click to read the 425 Business article >